Trautmann, Eric M.
O’Shea, Daniel J. http://orcid.org/0000-0002-1366-1743
Sun, Xulu http://orcid.org/0000-0003-3076-0994
Marshel, James H.
Crow, Ailey
Hsueh, Brian
Vesuna, Sam
Cofer, Lucas
Bohner, Gergő
Allen, Will
Kauvar, Isaac
Quirin, Sean
MacDougall, Matthew
Chen, Yuzhi
Whitmire, Matthew P.
Ramakrishnan, Charu http://orcid.org/0000-0002-3474-6332
Sahani, Maneesh http://orcid.org/0000-0001-5560-3341
Seidemann, Eyal http://orcid.org/0000-0002-4873-3882
Ryu, Stephen I.
Deisseroth, Karl http://orcid.org/0000-0001-9440-3967
Shenoy, Krishna V. http://orcid.org/0000-0003-1534-9240
Funding for this research was provided by:
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1F31NS089376-01)
United States Department of Defense | Defense Advanced Research Projects Agency (W911NF-14-2-0013)
Simons Foundation (325380, 543045)
Article History
Received: 23 September 2019
Accepted: 19 May 2021
First Online: 17 June 2021
Competing interests
: K.V.S. is a consultant to Neuralink Corp. and CTRL-Labs Inc. (now a part of the Facebook Reality Labs division of Facebook) and on the Scientific Advisory Boards of Mind-X Inc., Inscopix Inc. and Heal Inc. K.D. is on the scientific advisory board of Maplight Therapeutics. These entities did not support this work. Following this study, J.H.M. is now a member of the scientific advisory board of Bruker. M.M. is employed by Neuralink Corp. The remainder of the authors declare no competing interests (E.M.T, D.J.O, X.S, G.B., S.I.R, A.C., B.H., S.V., L.C., W.A, I.K., S.Q., M.M., Y.C., M.W. E.S., C.R., and M.S.).